Cullinan Oncology LLC (CGEM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $667.39M
Last updated: Nov 17, 2026 at 11:05 AM ET
Cullinan Oncology LLC (CGEM) Competitors
The companies most similar to Cullinan Oncology LLC are CytomX Therapeutics (CTMX), Candel Therapeutics (CADL) and Kura Oncology (KURA). By market cap, Cullinan Oncology LLC ranks 6th of the 13 companies on this page; Corvus Pharmaceuticals (CRVS) is the largest at $897.52M. The median P/E of the 3 companies with a P/E is 14.2x.
Peer Comparison
CGEM's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Cullinan Oncology LLC (CGEM) | $667.39M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| CytomX Therapeutics Inc (CTMX) | $444.73M | N/A | 31.0x | 0.0% | -32.8% | -71.7% | 0.00% |
| Candel Therapeutics Inc (CADL) | $486.37M | N/A | N/A | 0.0% | -43.5% | 0.0% | 0.00% |
| Kura Oncology Inc (KURA) | $713.90M | N/A | 8.0x | 0.0% | -1125.3% | 10.1% | 0.00% |
| Immix Biopharma Inc (IMMX) | $657.09M | N/A | N/A | 0.0% | -14.9% | 0.0% | 0.00% |
| Nuvectis Pharma Inc (NVCT) | $696.03M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Puma Biotechnology Inc (PBYI) | $401.70M | 15.0x | 1.6x | 10.3% | N/A | 1.1% | 0.00% |
| Climb Bio Inc (CLYM) | $608.53M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | $683.26M | N/A | 8.1x | -124.8% | -7.3% | 178.1% | 0.00% |
| Corvus Pharmaceuticals Inc (CRVS) | $897.52M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Olema Pharmaceuticals Inc (OLMA) | $662.30M | N/A | N/A | 0.0% | -53.8% | 0.0% | 0.00% |
| Rigel Pharmaceuticals Inc (RIGL) | $837.18M | 14.2x | 2.8x | 106.6% | 16.7% | 16.5% | 0.00% |
| CorMedix Inc (CRMD) | $370.64M | 6.3x | 0.9x | 15.5% | 13.9% | -47.7% | 0.00% |
| Peer median | $659.70M | 14.2x | 5.4x | 0.0% | -23.8% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Cullinan Oncology LLC, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| CytomX Therapeutics Inc (CTMX) | CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. | CTMX competitors |
| Candel Therapeutics Inc (CADL) | Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform... | CADL competitors |
| Kura Oncology Inc (KURA) | Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. | KURA competitors |
| Immix Biopharma Inc (IMMX) | Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology... | IMMX competitors |
| Nuvectis Pharma Inc (NVCT) | Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. | NVCT competitors |
| Puma Biotechnology Inc (PBYI) | Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States... | PBYI competitors |
| Climb Bio Inc (CLYM) | Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. | CLYM competitors |
| Adlai Nortye Ltd. American Depositary Shares (ANL) | Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. | |
| Corvus Pharmaceuticals Inc (CRVS) | Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. | CRVS competitors |
| Olema Pharmaceuticals Inc (OLMA) | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development... | OLMA competitors |
| Rigel Pharmaceuticals Inc (RIGL) | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. | RIGL competitors |
| CorMedix Inc (CRMD) | CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious... | CRMD competitors |
Frequently Asked Questions About CGEM
Who are Cullinan Oncology LLC's main competitors?
The companies most similar to Cullinan Oncology LLC include CytomX Therapeutics (CTMX), Candel Therapeutics (CADL), Kura Oncology (KURA), Immix Biopharma (IMMX) and Nuvectis Pharma (NVCT), listed from the closest match.
Who is Cullinan Oncology LLC's biggest competitor?
Corvus Pharmaceuticals (CRVS) is the largest of the similar companies at $897.52M; CytomX Therapeutics (CTMX) is the closest match by business profile, size, sector and industry.
How does CGEM stock compare with its competitors?
CGEM's net margin is 0.0% against a peer median of 0.0%.
Which of Cullinan Oncology LLC's competitors pays a higher dividend?
Cullinan Oncology LLC pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Cullinan Oncology LLC bigger than its competitors?
No. Cullinan Oncology LLC is 6th by market cap among the 13 companies on this page; the largest is Corvus Pharmaceuticals (CRVS) at $897.52M.
CGEM pages: Overview, Earnings, Forecast, Financials, Competitors